(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Pers Clendeninn Neil James	2. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below)			
400-1001 W. BROADWAY		3. Date of Earliest Transaction (Month/Day/Year) 06/08/2010								
(Street) VANCOUVER, A1 V6H 4B1		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transact Code (Instr. 8) Code	tion	4. Securi (A) or Di (Instr. 3, Amount	sposed o		Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and Amount		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transaction of			Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code Derivative		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial		
(Instr. 3)	Price of		(Month/Day/Year)					(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership		
	Derivative			Acquired								Security:	(Instr. 4)		
	Security			(A) or								Direct (D)			
				Disposed							*	or Indirect			
				of (D)							Transaction(s)	· · /			
				(Instr. 3, 4, and 5)							(Instr. 4)	(Instr. 4)			
				and 5)											
											Amount				
								Date	Expiration		or				
								Exercisable		Title	Number				
				C 1							of				
				Code	V	(A)	(D)				Shares				
stock															
option										Common				_	
(right to	\$ 14.2	06/08/2010		Α		3,500		<u>(1)</u>	06/08/2020	Stock	3,500	\$ 0	3,500	D	
										SIOCK					
buy)															

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Clendeninn Neil James 400-1001 W. BROADWAY VANCOUVER, A1 V6H 4B1	Х						

Signatures

Sandra Thomson as attorney-in-fact for Neil Clendeninn	06/09/2010	
**Signature of Reporting Person	Date	

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options shall vest in full on the earlier of June 8, 2011 or the date immediately prior to Oncogenex Pharmaceuticals, Inc.'s next annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.